Project Grant T32AI184303
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $2.959 million on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the Michigan Influenza Transmission Research Center's observational studies of human influenza transmission. The award funds three coordinated research projects examining influenza transmission through the epidemiologic triangle framework of pathogen, host, and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $2.284 million on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on microbial interactions combating antibiotic-resistant bacteria (MI-CARB). The research employs a systems biology approach to understand pathogenesis of nosocomial infections caused by three pathogen groups: vancomycin-resistant enterococci (VRE),...
- The National Institute of Allergy and Infectious Diseases awarded $151,760 to the Regents of the University of Michigan on December 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support postdoctoral research characterizing riboswitches in methicillin-resistant Staphylococcus aureus as potential antibiotic targets. The fellowship provides advanced, multidisciplinary training in RNA biology, structural biochemistry, and single-molecule fluorescence...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $411,078 on April 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model perinatal exposure to diverse pathogenic microbes and assess the functional programming of innate lymphoid cells, specifically group 1 innate lymphocytes and natural killer cells. The research addresses how early-life microbial exposure shapes immune system development and innate...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $516,410 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop precision biomaterials that enrich and monitor antigen-specific immune cells in vivo. The research addresses a critical gap in immunological assessment: current methods for measuring antigen-specific cells require expensive and time-consuming ex vivo expansion that can alter cell...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $186,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on infection-induced cell cycle diversion and macrophage inflammatory biogenesis. The award funds investigation into how bacterial infection of macrophages, specifically by methicillin-resistant Staphylococcus aureus (MRSA), triggers structural and biochemical...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the Regents of the University of Michigan $194,400 on April 1, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project examines the role of organelle membrane contact sites in macrophage antifungal immune responses, with particular focus on Candida albicans infection. Preliminary data indicate that the endoplasmic reticulum stress sensor IRE1A...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $690,883 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate leukotriene B4 signaling during directed neutrophil migration and inflammation in skin. The funded research examines how leukotriene B4 regulates both pro-inflammatory and anti-inflammatory phases during acute inflammation. The work builds on established findings that...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $195,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI201758). The recipient will develop a urea-inducible library of 217 transcription factors in Proteus mirabilis, a bacterium responsible for up to 44 percent of long-term catheter-associated urinary tract...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $131,842 on December 23, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate structural and biochemical factors guiding concanamycin A biosynthesis. The research elucidates the architecture of the concanamycin-producing polyketide synthase complex directly within bacterial cells using cryo-electron tomography, cross-linking mass spectrometry, and...
The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $329,539 on July 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support the Transdisciplinary Training in RNA and Infection (TRAIN) program. TRAIN integrates 32 preceptors from 14 departments across 5 schools and institutes at the University of Michigan to mentor six graduate students in RNA biology, infectious disease research, and drug development. The program delivers structured mentorship spanning from RNA mechanisms to clinical studies, supported partly by internal University of Michigan resources. Key components include a mini-sabbatical program in which trainees gain hands-on experience in collaborating labs, an industry internship program in partnership with the Rackham Graduate School, Innovation Partnerships, and at least five pharmaceutical companies, trainee-led seminars and an annual symposium where trainees select and host speakers, and comprehensive resources including specialized coursework in RNA and infectious diseases. The program builds on University of Michigan's existing strengths in RNA biomedicine and infectious diseases, addressing gaps in preparedness for emerging viral pathogens revealed by the COVID-19 pandemic and leveraging advances in mRNA vaccine technology. Work is performed in Ann Arbor, Michigan. The period of performance runs through June 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $329.5k | 7/24/26 |